株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ムスカリン性アセチルコリン受容体M4 (CHRM4):パイプライン製品の分析

Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 520778
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.68円で換算しております。
ムスカリン性アセチルコリン受容体M4 (CHRM4):パイプライン製品の分析 Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 81 Pages
概要

当レポートでは、ムスカリン性アセチルコリン受容体M4 (CHRM4)を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ムスカリン性アセチルコリン受容体M4 (CHRM4);概要

ムスカリン性アセチルコリン受容体M4 (CHRM4);治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別
  • 企業で開発中の製品

治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Anavex Life Sciences Corp
  • AstraZeneca Plc
  • Heptares Therapeutics Ltd
  • Karuna Pharmaceuticals Inc
  • NeuroHealing Pharmaceuticals Inc
  • 大日本住友製薬

薬剤プロファイル

休止中の製品

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Anavex Life Sciences Corp, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by Cerevel Therapeutics LLC, H2 2019
  • Pipeline by Karuna Therapeutics Inc, H2 2019
  • Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2019
  • Pipeline by NeuroSolis Inc, H2 2019
  • Pipeline by Presbyopia Therapies LLC, H2 2019
  • Pipeline by Sosei Heptares, H2 2019
  • Pipeline by Suven Life Sciences Ltd, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
目次
Product Code: GMDHC2062TDB

Summary

Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 17 molecules. The latest report Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2019, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 8 and 3 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Neurology, Pain, Parkinson's Disease, Presbyopia, Rett Syndrome, Sialorrhoea and Tuberous Sclerosis.

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)
  • The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
  • Anavex Life Sciences Corp
  • AstraZeneca Plc
  • Cerevel Therapeutics LLC
  • Karuna Therapeutics Inc
  • NeuroHealing Pharmaceuticals Inc
  • NeuroSolis Inc
  • Presbyopia Therapies LLC
  • Sosei Heptares
  • Suven Life Sciences Ltd
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
  • (aceclidine + tropicamide) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (trospium chloride + xanomeline) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • blarcamesine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CVL-231 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Agonize CHRM4 for Psychosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HTL-0016878 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSX-0527 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSX-0527f - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSX-0559 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSX-0559f - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for Psychosis and Cognitive Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tropicamide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-0467154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-6000918 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-6001852 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 04, 2019: Anavex Life Sciences presents ANAVEX2-73 (blarcamesine) data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 conference
  • Nov 19, 2019: Karuna Therapeutics' schizophrenia drug passes Phase II trial
  • Nov 18, 2019: Karuna Therapeutics announces KarXT met primary endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
  • Nov 17, 2019: Karuna Therapeutics schedules webcast and conference call to announce results from its phase 2 clinical trial of KarXT for the treatment of Psychosis in patients with Schizophrenia
  • Nov 14, 2019: Anavex Life Sciences receives Rare Pediatric Disease Designation from FDA for ANAVEX2-73 (blarcamesine) for the treatment of Rett Syndrome
  • Nov 06, 2019: Anavex Life Sciences announces publication of foundational data for ANAVEX2-73 (blarcamesine) in Rett Syndrome
  • Oct 21, 2019: Cerevel Therapeutics initiates phase 1b clinical trial of CVL-231, a M4 selective positive allosteric modulator in development for the treatment of schizophrenia
  • Oct 10, 2019: Anavex initiates ANAVEX 2-73 study in Alzheimer disease
  • Oct 02, 2019: Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX2-73 for the Treatment of Alzheimer's Disease
  • Sep 27, 2019: Anavex Life Sciences presented at the 6th Annual European Rett Syndrome Conference preliminary clinical efficacy data from the U.S. Rett Syndrome Phase 2 ANAVEX2-73 Study
  • Sep 16, 2019: Anavex Life Sciences announces preliminary clinical efficacy data of its U.S. phase 2 clinical trial of ANAVEX 2-73 in patients with Rett Syndrome
  • Sep 04, 2019: Anavex Life Sciences announces initiation of the EXCELLENCE ANAVEX 2-73-RS-003 clinical study in pediatric patients with Rett Syndrome
  • Jul 31, 2019: Anavex Life Sciences reports recent data review by the independent data safety monitoring board for its US phase 2 clinical trial of ANAVEX 2-73 in patients with Rett syndrome
  • Jul 29, 2019: Anavex Life Sciences receives positive opinion for orphan designation from the European Medicines Agency for ANAVEX2-73 for the treatment of rett syndrome
  • Jul 17, 2019: Anavex Life Sciences presents new clinical data identifying gut microbiota biomarkers asociated with improved clinical response in patients treated with ANAVEX2-73 at 2019 Alzheimer's Association International Conference (AAIC)
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer